Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24993020 | 0.83 | TSHR (0.33) | TSHR | |
| SCHEMBL28292849 | 0.81 | — | — | |
| SCHEMBL27480154 | 0.81 | TSHR (0.32) | TSHR | |
| SCHEMBL5390045 | 0.80 | CYP4F2 (0.34) | — | |
| SCHEMBL7907353 | 0.78 | ADH1A (0.30) | — | |
| SCHEMBL9751900 | 0.78 | ADH1A (0.30) | — | |
| SCHEMBL6335764 | 0.78 | ADH1A (0.30) | — | |
| SCHEMBL27289579 | 0.78 | — | — | |
| SCHEMBL29598878 | 0.77 | FFAR3 (0.35) | TSHR | |
| SCHEMBL12389948 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530226-B2 | Azepane inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-20 | — | — | US | disclosed |
| US-11220517-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-11 | — | — | US | disclosed |
| US-20200339594-A1 | Azepane Inhibitors Of Menin-MLL Interaction | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-29 | — | — | US | disclosed |
| US-20200172556-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220517-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | BMI1, MLLT1, MEN1 | TSHR 4515/4885 |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, MEN1 | TSHR 4435/4885 |
| US-20200172556-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, BMI1, MEN1 | TSHR 4479/4885 |
| US-11530226-B2 | Azepane inhibitors of menin-MLL interaction | MEN1, MLLT1, BMI1 | TSHR 4559/4885 |
| US-20200339594-A1 | Azepane Inhibitors Of Menin-MLL Interaction | MEN1, MLLT1, BMI1 | TSHR 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.